GO
Loading...

Enter multiple symbols separated by commas

Life Sciences

More

  • *Alexion offers $225.92 per Synageva share in cash and stock. May 6- Drugmaker Alexion Pharmaceuticals Inc agreed to buy Synageva BioPharma Corp for $8.4 billion at a hefty premium to expand in the lucrative market for drugs that treat rare diseases. The drug, whose marketing application is being reviewed in the United States and Europe, treats a rare and...

  • Two pharma giants merge in $8.4B deal Wednesday, 6 May 2015 | 8:01 AM ET
    Pharmaceuticals

    Alexion said it would buy Synageva for $8.4 billion to gain access to its experimental early-stage treatment for a rare metabolic disease.

  • May 6- Drugmaker Alexion Pharmaceuticals Inc said it would buy Synageva BioPharma Corp for $8.4 billion to boost its rare drug pipeline. Kanuma's marketing application is being reviewed in the United States and Europe. Recent deals involving rare disease companies include Teva Pharmaceutical Industries Inc's $3.5 billion purchase of Auspex...

  • Alexion Pharma to buy Synageva BioPharma for $8.4 bln Wednesday, 6 May 2015 | 6:54 AM ET

    May 6- Drugmaker Alexion Pharmaceuticals Inc said it would buy Synageva BioPharma Corp for $8.4 billion to gain access to its experimental early-stage treatment for a rare metabolic disease. Alexion's cash-and-stock offer values Synageva at $225.92 per share, representing a premium of 135.7 percent to the stock's close on Tuesday. The deal is expected to...

  • May 4- Corbus Pharmaceuticals Holdings Inc's experimental drug for cystic fibrosis, a rare lung-scarring disease, could be a real money spinner and pose a challenge to rival Vertex Pharmaceuticals Inc's successful treatment, Kalydeco. Corbus, a tiny biopharmaceutical company, received $5 million from the Cystic Fibrosis Foundation last month to develop...

  • April 30- The U.S. Food and Drug Administration on Thursday approved The Medicines Co's dry powder blood-clotting agent for use in hospital settings, a month after the treatment received approval in Europe. The approval comes at a time Medicines Co is facing a drop in sales of its lead product, Angiomax anticoagulant injection, which accounted for over 80...

  • FDA approves Medicines Co's blood clotting agent Thursday, 30 Apr 2015 | 5:47 PM ET

    April 30- The U. S Food and Drug Administration approved the Medicines Co's dry powder blood clotting agent for use in hospital settings, a month after the treatment received approval in Europe. The treatment, Raplixa, is a combination of two human plasma-derived blood-clotting proteins, fibrinogen and thrombin. Raplixa is used to control bleeding during...

  • April 29- The U.S. Food and Drug Administration said on Wednesday it approved an injection for "double chin" reduction, developed by Kythera Biopharmaceuticals Inc.. Submental, or below the chin, liposuction costs between $2,700 and $5,175, according to the American Society for Dermatologic Surgery. Last year, Kythera regained the rights to market the drug...

  • LONDON, April 28- An experimental shingles vaccine from GlaxoSmithKline is effective across all age groups, researchers said on Tuesday, boosting the prospects of a key product in the British drugmaker's development pipeline. Goldman Sachs analysts said in a report on Tuesday that efficacy across age groups could give HZ/su a meaningful edge over Zostavax,...

  • April 27- Drug developer Celladon Corp said it expected to announce lay-offs and cost cuts as its stock plunged to an all-time low after the company's lead experimental gene therapy to treat heart failure failed a key trial. Celladon lost nearly 80 percent of its market value in early trading on Monday, with the stock falling to a record low of $2.76.

  • *Celladon trial failure shows field remains high-risk. LONDON, April 27- GlaxoSmithKline is close to seeking European approval for a gene therapy drug to fight the immune deficiency disorder known as "bubble boy" disease, in the latest sign of a renaissance in the technology to fix faulty genes. Gene therapy last year won $3.0 billion of financing, up 510 percent on...

  • April 27- The U.S. Food and Drug Administration should not consider an accelerated review of Amgen Inc's marketing application for its skin cancer vaccine, FDA staff reviewers concluded in documents released on Monday, citing concerns over the design and results of a key study. The review comes two days before a panel of FDA advisers votes on whether the...

  • April 27- The U.S. Food and Drug Administration should not consider an accelerated review for drugmaker Amgen Inc's marketing application for its skin cancer vaccine, FDA staff reviewers concluded in documents released on Monday. The review comes two days before a panel of FDA advisers votes on whether the treatment, a cancer-killing virus called talimogene...

  • April 23- A unit of AstraZeneca Plc has teamed up with Juno Therapeutics Inc to develop combination treatments that use the body's immune system to kill cancer cells. The partnership between AstraZeneca's research and development arm MedImmune and Juno is the latest collaboration between companies intent on developing a new class of drugs known as...

  • Tekmira Ebola drug succeeds in small monkey study Wednesday, 22 Apr 2015 | 1:00 PM ET

    NEW YORK, April 22- An experimental Ebola drug from Tekmira Pharmaceuticals Corp cured all three monkeys intentionally infected with the virus, scientists reported on Wednesday, the first such success against the strain of Ebola in West Africa's 2014-2015 outbreak. Although other experimental treatments appeared to help Ebola patients last year,...

  • April 17- Drug developer Athersys Inc said its cell therapy failed in a mid-stage study testing it as a treatment for a type of stroke, sending its shares down more than 50 percent in premarket trading. Athersys said on Friday patients given the cell therapy did not show a significant difference from those given a placebo as measured by the Global Stroke Recovery...

  • FRANKFURT, April 17- A German regulator for new drugs has suspended the assessment of the Western world's first gene therapy, UniQure's Glybera, after an adviser to the European drugs watchdog voiced concern over the treatment. An adviser for biotech drugs to the European Medicines Agency, a so-called rapporteur, last week said in a report that Glybera, which is...

  • UPDATE 1-Aduro IPO pricing values drugmaker at $1 bln Tuesday, 14 Apr 2015 | 6:23 PM ET

    Aduro, which counts Johnson& Johnson and Swiss drugmaker Novartis AG among its investors, is selling all the 7 million shares in the offering. To gain access to Aduro's cancer immunotherapy technology, Novartis last month entered into a tie-up worth about $750 million with the company. Novartis Institutes for BioMedical Research Inc, an affiliate of Novartis,...

  • *Index Ventures clocks up 11 transactions since 2005. Ten years on from pioneering an ultra-lean business model focused on investing in "virtual" companies with a single experimental medicine, XO1's backer Index Ventures is chalking up some notable wins. The new model has grabbed attention as venture capitalists strive to improve returns in a notoriously...

  • UniQure's shares jumped more than 55 percent on Monday after Bristol-Myers said it would pick up a 4.9 percent stake in the company. UniQure's gene therapy drug, Glyberan, went on sale last year priced at 1.1 million euros. Bayer AG struck a gene therapy deal with Dimension Therapeutics in June, while France's Sanofi SA has a long-standing tie-up with Oxford...